Table 7.
Clinical and microbiologic outcomes among patients with baseline ESBL-producing and amino-R Escherichia coli characteristics (occurrence of primary and secondary endpoints) a .
| Endpoints | PTZ (n = 61) | Meropenem (n = 18) | Total (n = 79) | p-value |
|---|---|---|---|---|
| Primary efficacy endpoints | ||||
| Success | 47 (77%) | 15 (83.3%) | 62 (78.5%) | 0.569 |
| Failure | 3 (4.9%) | 1 (5.6%) | 4 (5.1%) | |
| Indeterminate | 11 (18%) | 2 (11.1%) | 13 (16.5%) | |
| Secondary efficacy endpoint—clinical endpoint response | ||||
| Success | 37 (60.7%) | 6 (33.3%) | 43 (54.4%) | 0.041 |
| Failure | 6 (9.8%) | 5 (27.8%) | 11 (13.9%) | |
| Indeterminate | 18 (29.5%) | 7 (38.9%) | 25 (31.6%) | |
| Secondary efficacy endpoint—microbiological endpoint response | ||||
| Success | 40 (65.6%) | 8 (44.4%) | 48 (60.8%) | 0.107 |
| Failure | 6 (9.8%) | 2 (11.1%) | 8 (10.1%) | |
| Indeterminate | 15 (24.6%) | 8 (44.4%) | 23 (29.1%) | |
a
Data are expressed as No. (%) of participants unless otherwise indicated.
The bold values means there is significant differences in this group of people.